Clinical and economic review of erlotinib in non-small-cell lung cancer-Reference-Cited by-同舟云学术

Clinical and economic review of erlotinib in non-small-cell lung cancer

Published:2012-08 Issue:4 Volume:12 Page:411-423
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Yeung Kai,Carlson Josh J

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1586/erp.12.42

Reference83 articles.

1. Cancer statistics, 2011

2. National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology: Non-Small-Cell Lung Cancer. National Comprehensive Cancer Network, USA (2012).

3. Treatment of Non-small Cell Lung Cancer-Stage IIIA

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and Antiproliferative Activities of Novel Substituted 5‐Anilino‐ α ‐Glucofuranose Derivatives;Chemistry & Biodiversity;2020-04

2. Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer;Translational Cancer Research;2020-02

3. DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines;BMC Cancer;2015-09-09

4. Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis;Tumor Biology;2015-06-04

5. Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells;International Journal of Radiation Biology;2014-06-25